Allison Hoffman Sells 14,483 Shares of Phreesia (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) General Counsel Allison Hoffman sold 14,483 shares of the company’s stock in a transaction on Friday, April 10th. The shares were sold at an average price of $8.07, for a total transaction of $116,877.81. Following the completion of the sale, the general counsel directly owned 163,485 shares in the company, valued at approximately $1,319,323.95. The trade was a 8.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Phreesia Price Performance

NYSE:PHR opened at $8.61 on Wednesday. Phreesia, Inc. has a one year low of $7.77 and a one year high of $32.76. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.53 and a current ratio of 1.53. The firm has a market cap of $523.14 million, a price-to-earnings ratio of 287.00 and a beta of 0.86. The firm’s fifty day moving average is $11.14 and its two-hundred day moving average is $16.50.

Phreesia (NYSE:PHR) last posted its quarterly earnings results on Monday, March 30th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.05). The business had revenue of $127.07 million during the quarter, compared to analysts’ expectations of $126.75 million. Phreesia had a net margin of 0.48% and a return on equity of 3.23%. Phreesia’s revenue for the quarter was up 15.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.11) earnings per share. Research analysts expect that Phreesia, Inc. will post -1.1 EPS for the current year.

Wall Street Analysts Forecast Growth

PHR has been the subject of a number of analyst reports. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $16.00 price objective (down from $24.00) on shares of Phreesia in a research report on Tuesday, March 31st. KeyCorp decreased their price objective on shares of Phreesia from $15.00 to $12.00 and set an “overweight” rating for the company in a research report on Monday. Stephens decreased their price objective on shares of Phreesia from $32.00 to $20.00 and set an “overweight” rating for the company in a research report on Tuesday, March 31st. Needham & Company LLC decreased their price objective on shares of Phreesia from $35.00 to $14.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Finally, BMO Capital Markets decreased their price objective on shares of Phreesia from $32.00 to $14.00 and set an “outperform” rating for the company in a research report on Tuesday, March 31st. Twelve analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Phreesia presently has a consensus rating of “Moderate Buy” and an average target price of $20.82.

Key Stories Impacting Phreesia

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Named to Becker’s Hospital Review 2026 list of “Revenue Cycle Management Companies to Know,” a credibility signal for Phreesia’s patient intake/revenue-cycle positioning that can help sales conversations and customer wins. Becker’s Listing
• Positive Sentiment: Large institutional holders have recently added to positions (Vanguard, Granahan, Franklin, Nuveen among others), which supports liquidity and signals confidence from professional investors. Institutional Ownership Details
• Neutral Sentiment: Insiders David Linetsky and General Counsel Allison Hoffman sold shares (April 10) under pre‑arranged Rule 10b5‑1 plans to cover tax withholding on vesting awards; sales were disclosed via SEC Form 4 and appear planned rather than opportunistic. Insider Form 4
• Neutral Sentiment: Recent quarterly results showed revenue growth (~15.9% y/y) and revenue roughly in line with expectations, but an EPS miss (0.02 vs. est. 0.07) and analysts’ negative near‑term EPS outlook keep sentiment mixed. Earnings Summary
• Negative Sentiment: Investor‑protection firms (Pomerantz LLP and Levi & Korsinsky) announced investigations into Phreesia concerning potential securities law issues; such probes often weigh on sentiment and can increase legal/settlement risk. Pomerantz Investigation Levi & Korsinsky Notice
• Negative Sentiment: Multiple analysts have cut price targets recently (e.g., Stephens, Wells Fargo, Mizuho, Canaccord, Robert W. Baird); KeyCorp lowered its target to $12 while keeping an overweight rating — the cuts reflect skepticism about near‑term recovery and help explain the depressed stock valuation versus historical highs. Analyst Moves

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in shares of Phreesia by 8.3% during the 3rd quarter. Vanguard Group Inc. now owns 5,704,786 shares of the company’s stock worth $134,177,000 after purchasing an additional 437,462 shares during the last quarter. New York State Common Retirement Fund raised its position in shares of Phreesia by 727.1% during the 3rd quarter. New York State Common Retirement Fund now owns 136,856 shares of the company’s stock worth $3,219,000 after purchasing an additional 120,309 shares during the last quarter. Squarepoint Ops LLC raised its position in shares of Phreesia by 243.6% during the 2nd quarter. Squarepoint Ops LLC now owns 100,922 shares of the company’s stock worth $2,872,000 after purchasing an additional 71,553 shares during the last quarter. Greenhouse Funds LLLP raised its holdings in Phreesia by 16.8% in the 3rd quarter. Greenhouse Funds LLLP now owns 3,882,527 shares of the company’s stock valued at $91,317,000 after acquiring an additional 557,265 shares during the last quarter. Finally, Bessemer Group Inc. raised its holdings in Phreesia by 1,065.9% in the 3rd quarter. Bessemer Group Inc. now owns 554,513 shares of the company’s stock valued at $13,043,000 after acquiring an additional 506,954 shares during the last quarter. Institutional investors and hedge funds own 92.10% of the company’s stock.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.